Hong‐Hong Yan

7.4k total citations · 2 hit papers
133 papers, 3.7k citations indexed

About

Hong‐Hong Yan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Hong‐Hong Yan has authored 133 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 108 papers in Pulmonary and Respiratory Medicine, 71 papers in Oncology and 26 papers in Cancer Research. Recurrent topics in Hong‐Hong Yan's work include Lung Cancer Treatments and Mutations (98 papers), Lung Cancer Diagnosis and Treatment (41 papers) and Lung Cancer Research Studies (38 papers). Hong‐Hong Yan is often cited by papers focused on Lung Cancer Treatments and Mutations (98 papers), Lung Cancer Diagnosis and Treatment (41 papers) and Lung Cancer Research Studies (38 papers). Hong‐Hong Yan collaborates with scholars based in China, United States and India. Hong‐Hong Yan's co-authors include Yi‐Long Wu, Jin‐Ji Yang, Qing Zhou, Wen‐Zhao Zhong, Jian Su, Xu‐Chao Zhang, Hai‐Yan Tu, Xue‐Ning Yang, Hua‐Jun Chen and Chong‐Rui Xu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Hong‐Hong Yan

125 papers receiving 3.7k citations

Hit Papers

Potential Predictive Value of TP53 and KRAS Mutation Stat... 2016 2026 2019 2022 2016 2023 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
    2016 741 citations Zhong‐Yi Dong, Wen‐Zhao Zhong et al. Clinical Cancer Research profile →
  2. Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study
    2023 110 citations Hanmin Wang, Junwei Su et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hong‐Hong Yan China 31 2.8k 2.5k 870 866 223 133 3.7k
Venice Archer United Kingdom 9 3.6k 1.3× 3.6k 1.4× 919 1.1× 663 0.8× 276 1.2× 16 4.6k
Jin‐Ji Yang China 36 3.9k 1.4× 3.5k 1.4× 1.2k 1.4× 1.1k 1.2× 306 1.4× 146 4.9k
Willemijn S.M.E. Theelen Netherlands 16 3.3k 1.2× 3.0k 1.2× 998 1.1× 873 1.0× 385 1.7× 33 4.4k
Chong‐Rui Xu China 27 3.5k 1.2× 3.1k 1.2× 1.0k 1.2× 931 1.1× 202 0.9× 122 4.4k
Jordi Remón France 34 2.4k 0.8× 2.1k 0.9× 1.0k 1.2× 977 1.1× 261 1.2× 175 3.7k
Davey B. Daniel United States 19 2.1k 0.7× 2.2k 0.9× 538 0.6× 688 0.8× 362 1.6× 82 3.3k
Oleg Gladkov Russia 18 2.3k 0.8× 1.8k 0.7× 1.8k 2.1× 1.1k 1.3× 242 1.1× 65 3.7k
Mauro Zukin Brazil 13 2.8k 1.0× 2.4k 1.0× 748 0.9× 519 0.6× 111 0.5× 38 3.5k
Andrew Weickhardt Australia 23 2.3k 0.8× 2.3k 0.9× 967 1.1× 527 0.6× 169 0.8× 111 3.4k
Antoine Thiery-Vuillemin France 24 2.4k 0.8× 2.0k 0.8× 1.2k 1.4× 985 1.1× 208 0.9× 155 3.7k

Countries citing papers authored by Hong‐Hong Yan

Since Specialization
Citations

This map shows the geographic impact of Hong‐Hong Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong‐Hong Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong‐Hong Yan more than expected).

Fields of papers citing papers by Hong‐Hong Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hong‐Hong Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong‐Hong Yan. The network helps show where Hong‐Hong Yan may publish in the future.

Co-authorship network of co-authors of Hong‐Hong Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Hong‐Hong Yan. A scholar is included among the top collaborators of Hong‐Hong Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong‐Hong Yan. Hong‐Hong Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liu, Zhijie, Linbo Zhang, Hong‐Hong Yan, et al.. (2025). One-step fabricated multifunctional nanocomposite coatings with dynamic dewetting and active deicing for harsh environments. Progress in Organic Coatings. 206. 109386–109386. 1 indexed citations
3.
4.
Feng, William W., Janice J.N. Li, Hong‐Hong Yan, et al.. (2024). PL04.10 Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial. Journal of Thoracic Oncology. 19(10). S6–S6. 2 indexed citations
5.
Deng, Jie, Hong‐Hong Yan, Ming‐Yu Yang, et al.. (2023). WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901). Journal of Thoracic Oncology. 18(11). S38–S39. 1 indexed citations
6.
Deng, Jia‐Yi, Lingling Yang, Zhihong Chen, et al.. (2023). Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 11(7). e007218–e007218. 23 indexed citations
7.
8.
Su, Junwei, Zhi Xie, Hanmin Wang, et al.. (2022). Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer. Thoracic Cancer. 13(11). 1619–1630. 11 indexed citations
9.
Tang, Wen‐Fang, Junxin Lin, Zhong‐Yi Dong, et al.. (2019). P1.01-81 A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients with Lung Cancer. Journal of Thoracic Oncology. 14(10). S391–S391. 1 indexed citations
10.
Zheng, Mei-Mei, Yang-Si Li, Ben‐Yuan Jiang, et al.. (2019). Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. Journal of Thoracic Oncology. 14(5). 924–932. 75 indexed citations
11.
Xu, Chong‐Rui, Mingfeng Zhang, Xiaoxiao Peng, et al.. (2018). EGFR mutations in early‐stage and advanced‐stage lung adenocarcinoma: Analysis based on large‐scale data from China. Thoracic Cancer. 9(7). 814–819. 42 indexed citations
12.
Tu, Hai‐Yan, Ming Fu, Wen‐Zhao Zhong, et al.. (2018). Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer. Journal of Cancer. 9(17). 2987–2993. 2 indexed citations
13.
Zhang, Yichen, E‐E Ke, Zhihong Chen, et al.. (2017). P3.02b-095 Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs. Journal of Thoracic Oncology. 12(1). S1249–S1249.
14.
Zhong, Wen‐Zhao, Xue‐Ning Yang, Hong‐Hong Yan, et al.. (2017). P1.05-046 Randomized Study of Adjuvant Docetaxel vs. Observation for Completely Resected Stage IB-IIIa NSCLC with 11 Years' Median Follow-Up. Journal of Thoracic Oncology. 12(1). S642–S643. 1 indexed citations
15.
Dong, Song, Ning Zhao, Wei Deng, et al.. (2017). Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study. World Journal of Surgical Oncology. 15(1). 12–12. 2 indexed citations
16.
Dong, Zhong‐Yi, Wen‐Zhao Zhong, Xu‐Chao Zhang, et al.. (2016). Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research. 23(12). 3012–3024. 741 indexed citations breakdown →
17.
Huang, Ling, Shejuan An, Zhihong Chen, et al.. (2014). MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation. Journal of Thoracic Oncology. 9(5). 725–728. 29 indexed citations
18.
Su, Jian, Xu‐Chao Zhang, Shejuan An, et al.. (2014). Detecting the spectrum of multiplex gene mutations in non-small cell lung cancer by Snapshot assay. Chinese Journal of Cancer. 33(7). 346–50. 13 indexed citations
19.
Chen, Hua‐Jun, Jin‐Ji Yang, Hong‐Hong Yan, et al.. (2013). Feasibility of computed tomography‐guided core needle biopsy in producing state‐of‐the‐art clinical management in Chinese lung cancer. Thoracic Cancer. 5(2). 155–161. 3 indexed citations
20.
Lin, Huan, Wen‐Zhao Zhong, Xue‐Ning Yang, Hong‐Hong Yan, & Yi‐Long Wu. (2011). Forecasting Model of Risk of Cancer in Lung Cancer Pedigree in a Case-control Study. SHILAP Revista de lepidopterología. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Venice Archer Breakdown of academic impact, for papers by Jin‐Ji Yang Breakdown of academic impact, for papers by Willemijn S.M.E. Theelen Breakdown of academic impact, for papers by Chong‐Rui Xu Breakdown of academic impact, for papers by Jordi Remón Breakdown of academic impact, for papers by Davey B. Daniel Breakdown of academic impact, for papers by Oleg Gladkov Breakdown of academic impact, for papers by Mauro Zukin Breakdown of academic impact, for papers by Andrew Weickhardt Breakdown of academic impact, for papers by Antoine Thiery-Vuillemin
Rankless by CCL
2026